Great Western Mining begins drilling at key Nevada prospects (LON:GWMO)
10 September 2025
Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.
GSK plc (LON/NYSE: GSK) and Aiolos Bio, Inc. has announced that they have entered into an agreement under which GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focused on addressing..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 21.2% according to Jefferies.Jefferies set a target price of 12,500 GBX for the company, which when compared to the..
GSK plc with ticker (LON:GSK) now has a potential upside of 8.2% according to Barclays.Barclays set a target price of 1,575 GBX for the company, which when compared to the..
AstraZeneca plc (LON:AZN) and Ionis’ Wainua (eplontersen) has been approved in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN..
GSK plc with ticker (LON:GSK) now has a potential upside of 12.9% according to Berenberg Bank.Berenberg Bank set a target price of 1,650 GBX for the company, which when compared..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 23.5% according to Jefferies.Jefferies set a target price of 12,500 GBX for the company, which when compared to the..
GSK plc (LON/NYSE: GSK) has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted for review a regulatory application to extend the indication of GSK’s respiratory syncytial..
AstraZeneca plc (LON:AZN) has entered into a definitive agreement to acquire Icosavax, Inc. (NASDAQ: ICVX), a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein..
GSK plc (LON/NYSE: GSK) has announced the European Commission (EC) has granted marketing authorisation for Jemperli (dostarlimab) in combination with carboplatin-paclitaxel (chemotherapy), for the treatment of adult patients with mismatch..
AstraZeneca plc (LON:AZN) has decided to discontinue the STABILIZE-CKD and DIALIZE-Outcomes Phase III evidence trials for Lokelma (sodium zirconium cyclosilicate). The decision was made due to substantially increased enrolment timelines..
GSK plc (LON/NYSE: GSK) has announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for..
ConvaTec Group PLC with ticker (LON:CTEC) now has a potential upside of 28.4% according to Berenberg Bank.Berenberg Bank set a target price of 290 GBX for the company, which when..
GSK plc with ticker (LON:GSK) now has a potential upside of 12.1% according to Barclays.Barclays set a target price of 1,575 GBX for the company, which when compared to the..
Hikma Pharmaceuticals Plc with ticker (LON:HIK) now has a potential upside of 22.2% according to RBC Capital Markets.RBC Capital Markets set a target price of 2,150 GBX for the company,..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 31.9% according to Barclays.Barclays set a target price of 13,500 GBX for the company, which when compared to the..
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast..
GSK plc with ticker (LON:GSK) now has a potential upside of 9.7% according to Barclays.Barclays set a target price of 1,575 GBX for the company, which when compared to the..
HALEON PLC with ticker (LON:HLN) now has a potential upside of 20.2% according to Barclays.Barclays set a target price of 391 GBX for the company, which when compared to the..
AstraZeneca plc (LON:AZN) has announced its 9M and Q3 2023 results. Revenue and EPS summary 9M 2023 Q3 2023 % Change % Change $m Actual CER[1] $m Actual ..
AstraZeneca plc (LON:AZN) and Eccogene have entered into an exclusive licence agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) for the treatment of obesity, type-2..
